The Washington Capitals have an important bit of business to attend to before the NHL's trade deadline: firming up the goaltending position.
The Washington Capitals have an important bit of business to attend to before the NHL's trade deadline: firming up the goaltending position.
CHICAGO — The family of 12-year-old Tamir Rice, who was shot and killed by Cleveland police in 2014, asked the Justice Department on Friday to reopen the case into his death after it was closed in the waning weeks of the Trump administration. In late 2020, federal prosecutors said they would not bring charges against the two police officers involved, saying video of the shooting was of too poor a quality for them to conclusively establish what had happened. There were no other prosecutions in the case. In December 2015, a grand jury declined to bring criminal charges against the officers. Rice's family said in a letter to the Justice Department that it believes Trump officials were uninterested in seeking justice for him because of political reasons and made the case needlessly complicated. “The truth is this case is tragically simple. Tamir Rice was a boy. On November 22, 2014, he was doing something many boys enjoy: playing with a toy gun in a park near his house,” attorneys for the family wrote in the letter. Rice was Black, and the police officer who shot him was white. The shooting sparked community protests about the police treatment of Black people, especially after a grand jury decided not to indict the officer or his partner. “I’m still in so much pain because no one has been held accountable for the criminal act that took his life," Rice's mother, Samaria Rice, said in a statement. “I’m asking DOJ to reopen the investigation into my son’s case; we need an indictment and conviction for Tamir’s death.” The family's request puts pressure on Attorney General Merrick Garland and the Biden administration to begin publicly delivering on a commitment to combat racial discrimination in policing. Garland has said America doesn’t “yet have equal justice." But reopening the case could be complicated. “The election of President Biden, your appointment, and your commitment to the rule of law, racial justice, and police reform give Tamir’s family hope that the chance for accountability is not lost forever,” the family said in the letter. The Justice Department did not immediately respond to a request for comment on Friday. Rice was playing with a pellet gun outside a recreation centre in Cleveland on Nov. 22, 2014, when he was shot and killed by Officer Timothy Loehmann seconds after Loehmann and his partner, Officer Frank Garmback, arrived. The officers had been dispatched to the recreation centre after a man drinking beer and waiting for a bus called 911 to report that a “guy” was pointing a gun at people. The caller told a 911 dispatcher that it was probably a juvenile and the gun might be “fake,” though that information was never relayed to the officers. To bring federal civil rights charges in cases like these, the Justice Department must prove that an officer’s actions willfully broke the law and are not simply the result of a mistake, negligence or bad judgment. It has been a consistently tough burden for federal prosecutors to meet across both Democratic and Republican administrations, with the Justice Department declining criminal charges against police officers in other high-profile cases in recent years, including in the deaths of Eric Garner in New York City and Michael Brown in Ferguson, Missouri. In Rice's case, the Justice Department said poor-quality surveillance video recorded in the area where the shooting took place prevented prosecutors from being able to conclusively determine whether Rice was or was not reaching for his toy gun just prior to being shot. The two officers who were investigated told authorities soon after the shooting that Rice was reaching for the gun prior to being shot and was given multiple commands to show his hands. But the video, while grainy, shows what prosecutors need to know, said Zoe Salzman, an attorney with Emery Celli Brinckerhoff Abady Ward & Maazel, which is working with Rice's family. “It is very clear on the most important points,” she said. The timing, for one. It shows that Loehmann was primed to shoot within one or two seconds after encountering Rice, and he didn't pause to investigate. She said the officers' claims they gave Rice commands were proven untrue, and prosecutors included them as fact. But the letter from the Rice family’s attorneys said the Justice Department’s explanation was designed to make the case seem as “complicated as possible,” in an effort to run out the clock on certain federal charges. The letter asks that federal prosecutors convene a grand jury to consider charges against the police officers. Salzman said the family hopes Cleveland would also reconsider charges but feels its best chance is with the federal government. “All the Rice family is asking for here is a chance for justice," she said. “Again and again politics trump justice. All they asked for is an honest investigation and a fair presentation of the evidence to a grand jury.” Colleen Long, The Associated Press
The "China Household Care Market (Fabric Care, Home Care & Personal Hygiene): Insights & Forecast with Potential Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.
Sunshine State’s Sizable Retirement Population at RiskBOCA RATON Fla., April 16, 2021 (GLOBE NEWSWIRE) -- Florida ranked among the states with the highest COVID-19 infection rates for younger residents in 2020, putting the state’s large elderly population at an increased risk for the coronavirus, according to a study from a researcher at Florida Atlantic University. Florida counties with younger populations experienced higher COVID-19 infection rates among residents under 25 years old, with a 4.3 percent infection rate last year that was 33 percent higher than national averages, said Patrick Bernet, Ph.D., an associate professor of health administration in FAU’s College of Business. In addition, the study, published in the Journal of Public Health Management & Practice, revealed that the younger counties had higher infection, emergency room and hospitalization rates among residents over age 64, while older counties experienced reduced infection rates for all ages and decreased over age 64 emergency room and hospitalization rates. Bernet also found that former U.S. President Donald Trumpʼs vote share in Florida was associated with higher infection rates for all and higher over age 64 emergency room, hospitalization and mortality rates. The Sunshine State supported the Republican presidential candidate in both 2016 and 2020, so politically associated health behaviors are relevant for this study, he added. Bernet believes audience- and age-specific messaging can help reduce the pandemic’s toll. “There has been no concerted effort to communicate just how dangerous each single infection is – no matter the person’s age, race, income or gender,” he said. “It takes just 60 links in the infection chain for the disease to find its way to patients it can kill – who are disproportionately older or Black so either you're the unlucky No. 60 or you’re a mule who brought the disease one step closer.” As of December 2020, Florida’s 67 counties recorded 1.3 million COVID-19 infections and 21,000 associated deaths. The study arranged the state’s 2020 COVID-19 cases into age-specific county rates and supplemented that data with socioeconomic and demographic characteristics, as well as 2020 presidential voting results. Officials can use the results of this research to drive decisions about public health resource allocation and vaccine distribution, ultimately reducing “COVID-19 infections and deaths for all, minimizing the economic and human costs of the pandemic,” the study states. CONTACT: Paul Owers Florida Atlantic University College of Business 561-221-4090 firstname.lastname@example.org
In a new interview, BNY Mellon Wealth Management CEO Catherine Keating tamped down concern about inflation, saying the price hikes will be temporary. She pointed to two trends that predate the pandemic: an aging population and rising debt.
Hong Kong pro-democracy figures given jail terms of up to 18 monthsMedia mogul Jimmy Lai and veteran activist Lee Cheuk-yan each sentenced to 12 months over protests Martin Lee, left, and Jimmy Lai, two of the people sentenced on Friday. Photograph: Anthony Kwan/Getty
Dow Closes Above 34K on Strong Retail, Jobs Data
In the Heights will launch the Tribeca Film Festival on June 9 before it opens around the country on June 11
Lin-Manuel Miranda's Jon M. Chu-directed musical will finally debut at Tribeca.
Vancouver, British Columbia--(Newsfile Corp. - April 16, 2021) - Upco International Inc. (CSE: UPCO) (OTC Pink: UCCPF) (FSE: U06) ("Upco") is pleased to inform shareholders of corporate updates and strategies. These documents can be accessed from the SEDAR website at www.sedar.com.Upco International Inc, in response to a query from BCSC, would like to communicate a better disclosure on its Annual General Meeting procedures.As part of the customary business undertaken in the Annual General Meeting, ...
BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that it will host a virtual R&D Day at 1:00 p.m. ET on Thursday, April 22, 2021. Aprea’s R&D Day will be presented by Christian S. Schade, Chairman and Chief Executive Officer, and Eyal C. Attar, Chief Medical Officer, with a focus on the Company’s analysis of its recently completed Phase 3 MDS trial and the continued progress across its ongoing research and clinical development pipeline. The live webinar will begin at 1:00 pm Eastern Time and last approximately one hour. Registration is accessible on the Events page of Aprea’s website. Following the webinar, a replay will be available for a limited time on Aprea’s website. About Aprea Therapeutics, Inc. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors. Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for myelodysplastic syndromes (MDS), Orphan Drug and Fast Track designations from the FDA for acute myeloid leukemia (AML), and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration. For more information, please visit the company website at www.aprea.com. The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. About p53, eprenetapopt and APR-548 The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors. These mutations are often associated with resistance to anti-cancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer. Eprenetapopt (APR-246) is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein – by restoring wild-type p53 conformation and function – thereby inducing programmed cell death in human cancer cells. Pre-clinical anti-tumor activity has been observed with eprenetapopt in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others. Additionally, strong synergy has been seen with both traditional anti-cancer agents, such as chemotherapy, as well as newer mechanism-based anti-cancer drugs and immuno-oncology checkpoint inhibitors. In addition to pre-clinical testing, a Phase 1/2 clinical program with eprenetapopt has been completed, demonstrating a favorable safety profile and both biological and confirmed clinical responses in hematological malignancies and solid tumors with mutations in the TP53 gene. A pivotal Phase 3 clinical trial of eprenetapopt and azacitidine for frontline treatment of TP53 mutant MDS has been completed and failed to meet the primary endpoint of complete remission. Additional clinical trials in hematologic malignancies and solid tumors are ongoing. Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, Orphan Drug and Fast Track designations from the FDA for AML, and Orphan Drug designation from the European Medicines Agency for MDS, AML and ovarian cancer. APR-548 is a next-generation small molecule p53 reactivator. APR-548 has demonstrated high oral bioavailability, enhanced potency relative to eprenetapopt in TP53 mutant cancer cell lines and has demonstrated in vivo tumor growth inhibition following oral dosing of tumor-bearing mice. Enrollment in a Phase 1 clinical trial of APR-548 is anticipated to begin early in the second quarter of 2021. Forward-Looking Statement Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our study analyses, clinical trials, regulatory submissions and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies, risks associated with the coronavirus pandemic and the other risks set forth in our filings with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Source: Aprea Therapeutics, Inc. Corporate Contacts: Scott M. Coiante Sr. Vice President and Chief Financial Officer 617-463-9385 Gregory A. Korbel Chief Business Officer 617-463-9385
CHICAGO, April 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the full year ended December 31, 2020. 2020 Financial Highlights: Revenue for 2020 increased 40% to $55.4 Million, versus $39.7 for the same period last yearGross profit for 2020 increased 120% to $8.1 million, versus $3.7 million for 2019Operating income improved by $3.0 million to $2.7 million, compared to an operating loss of $0.3 million for the same period last yearNet income attributable to common stockholders was $0.8 million, or $0.06 per share for 2020, compared to net loss of $3.3 million or ($0.25) per share for 2019As of December 31, 2020, the Company had working capital of $6.0 million versus a working capital deficit of $7.1 million as of December 31, 2019 Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated, “I am pleased to report we generated 40% year-over-year revenue growth and achieved profitability for 2020 despite the impact of COVID-19 on the global markets. We have successfully navigated the pandemic and are on a solid growth trajectory heading into 2021. Our proprietary line of nutraceuticals and food supplements, Sky Premium Life, continues to expand and we now have over 70 SKUs. We expect to reach 150 SKUs by the end of 2021 and believe the recent as well as upcoming additions to our portfolio will become major drivers of our growth going forward. In addition to introducing new high margin pharmaceutical, nutraceutical and food supplement products, we have built a robust distribution network, which now includes relationships with over 160 wholesale pharmaceutical distributors across Europe’s largest markets, having access to over 40,000 pharmacies. In addition, we plan to expand to new global markets later this year.” “Overall, we have built a highly scalable business model and look forward to further enhancing profitability and cash flow as we leverage our fixed cost infrastructure and gain economies of scale. We have invested in and now operate 3 state-of-the-art warehouses with advanced automation technology that substantially expands our current capacity and throughput to support our planned growth. We remain highly encouraged by the outlook for the business and look forward to providing further updates as developments unfold.” Consolidated Statements of Operations and Comprehensive Income (Loss) Years Ended December 31, 2020 2019 REVENUE $55,406,337 $39,676,385 COST OF GOODS SOLD 47,345,957 36,014,116 GROSS PROFIT 8,060,380 3,662,269 INCOME (LOSS) FROM OPERATIONS 2,714,293 (255,809)NET INCOME (LOSS) 820,786 (3,298,965)BASIC NET INCOME (LOSS) PER SHARE $0.06 $(0.25)DILUTED NET INCOME (LOSS) PER SHARE $0.06 $(0.25)WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING Basic 13,270,097 13,273,596 Diluted 13,307,794 13,273,596 About Cosmos Holdings, Inc. Cosmos Holdings Inc., is an international pharmaceutical company, with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices and an extensive, established EU distribution network. The Company identifies, acquires, develops and commercializes products that improve patients' lives and outcomes and has an extensive network of clients in Germany, United Kingdom, United Arab Emirates, Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, Netherlands, and Greece. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece, Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could”, are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: COSM@crescendo-ir.com
Pompano Beach, FL, April 16, 2021 (GLOBE NEWSWIRE) -- Brownie’s Marine Group, Inc. (OTCQB: BWMG), a leading developer, manufacturer and distributor of tankless dive equipment and high-pressure air and industrial compressors in the marine industry, today announced a business update of several of their key business units. Brownie’s Marine Group and its subsidiaries have a core focus on innovation with an aim towards enabling our customers to explore “The Next Atmosphere” more easily. We look to provide our customers with the best options to fill their air tanks while having safe, family friendly, fun. This core focus is what drives the BMG companies to share the lifestyle of life under the surface. BLU3, Inc. There are several positive developments with BLU3’s NEMO. To date, our worldwide dealer network has expanded to 40 dealers. We expect the network will continue to grow.Our social media campaign also continues to grow with more than 10 active posters creating content for all of their channels across Facebook, Instagram, YouTube and Tik Tok. NEMO related content has had well over a million views on all platforms to date.NEMO sales on Amazon have shown a steady increase since its introduction to the platform in November 2020. NEMO is now listed or approved to list on Amazon.com US, Canada, Mexico, UK and Europe. NEMO is consistently listed as one of the top 25 Best Sellers ranked in Dive Packages on Amazon.com, as well as a top “Most Wished for Item” in the Diving Package category.Average monthly unit sales on Amazon.com for Q1-2021 have increased 78.6% as compared to the average monthly sales in November and December of 2020.BLU3 is on target for a Q3 launch of its next-generation product, the NOMAD, the big brother to the NEMO product that can take a diver to 33 feet for up to one hour on one charge. NOMAD will remain fully portable and airline friendly. NOMAD is expected to arrive in factory during the second quarter and production line plans are in process for our facility in Pompano Beach, Florida. Brownie’s Third Lung (“BTL”) BTL introduced the Sea LiOn 3.0 tm in June of 2020, which is the only battery powered surface supplied air system, to support three divers to 33 feet for more than 2 hours, on the market. Average unit sales per month increased 155% following the launch. Average monthly sales of the two diver Sea LiOn VS averaged 5.3 units per month from June through December of 2019, while Sea LiOn 3.0 tm sales during the same period in 2020 averaged 13.7 units per month.The Sea LiOn 3.0 tm retails for $5,995 and represents a 10% price increase over the Sea LiOn VS.BTL has adopted an “Explore the Next Atmosphere” slogan as an introduction to the new ‘”PRO” line of floating surface supplied air systems.With safety in mind, BTL has reconfigured its Standard models, the Sea LiOn 3.0 tm, the Explorer (formerly 390X), the Pioneer (formerly 285X), and the Scout (formerly 285BE), with a reduced downline to encourage divers to stay within the No Decompression Limit (NDL) zone (not more than 33 ft). A diver should be formally trained to dive below that level and have other safety tools available.“PRO” packages have been developed for more experienced divers, which include a longer downline, a personal dive computer for each diver, and an alternate air source for each diver. We are the first in our industry to develop this type of program and will continue to innovate with diver safety in mind. LW America’s LW America’s (“LWA”) continues to innovate within the diving and yachting industries to supply best in class sources of High Pressure compressed air systems using L&W compressors as the core for all of their products. LWA has developed a Boat Integrated Air System (BIAS), that is a perfect solution for the Yachting industry which solves for any air requirements needed on any Yacht. One YachtPro High Pressure compressor can service all of the typical items on a yacht that would normally be powered by 3-5 compressors.The customized system will fill dive tanks, provide air for the toys, doors, engine start and power the air horn. Custom installations will be co-marketed by yacht brokers, yacht servicing facilities, and sold directly to the yacht manufacturers.LWA also looks to meet the consumer right where they live. We have developed the YachtPro 110/220 to give the end-user the ability to fill their high-pressure breathing air tanks from the comfort of their garage. These units were specifically designed to operate on the power that is available in a home and have all of the safety features necessary to make tank filling easy and safe without the hassle of waiting in line to have your tank filled.The YachtPro 110/220 will launch during this second quarter of 2021. BTL and BLU3 are also focusing their growth efforts toward direct consumer interaction with an expanded social media presence via the use of influencers to increase product visibility. The BMG group of companies will continue to increase their social media footprint as the year continues. We encourage you to follow us on all our social media channels, and we want to thank all of our loyal customers who have come up with their own content as they enjoy our products and share it with the world. Follow us on: Twitter: @browniesmarine @diveblu3 $BWMG Instagram:@diveblu3 @browniesthirdlung @browniesmarinegroup Tik Tok: @diveblu3 Source: Brownie’s Marine Group, Inc.Contact Information: (954)-email@example.com
The "Online Food Delivery Packaging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
"I lost all the dreams and hopes that a mom has for a son. I lost my motherhood and I'm mourning it all," Rene Marsh said
Radnor, Pennsylvania--(Newsfile Corp. - April 16, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Investor ...
‘Sleep well skip’: Yeovil still raw before first game since captain’s tragic deathClub are preparing to play on Saturday after paying tribute to Lee Collins with his family at the stadium this week Tributes to Lee Collins at Yeovil’s Huish Park stadium, including a written note from the manager, Darren Sarll. Photograph: Simon Galloway/PA
Two senior Democratic senators will introduce legislation on Friday that would reassert Congress' oversight of international weapons deals, after President Joe Biden's administration decided to go ahead with a $23 billion sale to the United Arab Emirates that had worried lawmakers, congressional aides said. The bill, seen by Reuters, will be introduced by Senators Bob Menendez, chairman of the Senate Foreign Relations Committee, and Dianne Feinstein, a senior member of the intelligence committee.
The "World Gas Map, 2021 Edition" map has been added to ResearchAndMarkets.com's offering.
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Laboratory Information Management System Market Report. The global laboratory information management system market by revenue is expected to grow at a CAGR of approx.New York, April 16, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Laboratory Information Management System (LIMS) Market - Global Outlook and Forecast 2021-2026" - https://www.reportlinker.com/p06063361/?utm_source=GNW 12 % during the period 2020–2026. The growing automation in laboratories, technological advancements in LIMS, the need for regulatory compliance, and increasing R&D spending are the key drivers boosting the market growth. However, the growing demand for managing laboratory data via cloud-based solutions is a significant factor boosting the market growth. The storage of data via cloud-based solutions is reliable, agile, and secure. There is an increase in the adoption of cloud-based LIMS among healthcare laboratories. These solutions offer a host of benefits, including reliability, security, and constant data storage access. A large volume of data due to the increase in the number of patients undergoing diagnostics has increased complexities in workflow management. LIMS has proved highly beneficial for laboratories during the COVID-19 pandemic. Laboratories equipped with LIMS have constantly been performing the diagnostics faster with reducing turnaround times. This has a major impact on reducing the quarantine period of suspected patients and initiating a proper treatment of COVID-19 positive patients. The following factors are likely to contribute to the growth of the laboratory information management systems market during the forecast period: • Introduction of LIMS packages addressing COVID-19 Labs • Increase in Demand for Genomic LIMS • Usage of LIMS in Medical Cannabis Industry • Adoption of Cloud-based LIMS The study considers the global laboratory information management systems market’s present scenario and its market dynamics for the period 2020?2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market. Global Laboratory Information Management System Market Segmentation The global laboratory information management system market research report includes a detailed segmentation by products, components, deployment, end-users, geography. Broad-based laboratory information management systems market share accounts for 62% of the global LIMS market in 2020. These solutions are entirely configurable and customized software, featuring a comprehensive range of functionalities and modules. Global enterprises are the major end-users of these solutions as they must integrate multiple LIMS applications from several segments. The demand is growing as modern LIMSs help to connect several applications under a single system, thereby helping enterprises to operate efficiently, share and secure data, develop standard operating procedures, manage day-to-day accounts. A major advantage of broad-based solutions is cost-efficiency. These solutions involve low maintenance with multiple labs sharing a single LIMS solution. North America expects to account for a revenue share of over USD 523 million by 2026. The presence of over 530 regenerative medicine companies involving the use of advanced infrastructure such as LIMS to handle a large number of samples and track the status of the sample is likely to drive the demand. Industry-specific LIMSs expect to grow at a CAGR of approx. 12% during 2020–2026. They are exclusive and are specially designed for industries. These systems or solutions are observing high demand from agricultural and contract research organizations. The cloud-based LIMS market is expected to grow at a CAGR of over 12% during 2020–2026. Vendors are increasingly adopting cloud-based LIMS to minimize expenditure and save time and resources. The demand for data safety and security has driven companies to invest mainly in the cloud-based infrastructure, which is another factor driving the adoption. In 2020, web-based LIMSs accounted for the share of over 41% in the global LIMS market. The implementation of remote LIMS helps laboratories reduce risks, develop business opportunities, and offer flexibility in working. These solutions help companies and organizations to run laboratories remotely and from multiple locations. With the outbreak of the COVID-19 pandemic, most laboratories conducted their data-oriented processes from home using cloud-hosted, remote-based LIMSs. Several laboratories, CROs, research institutes, and pharma and biotech companies have worked uninterruptedly during the pandemic, thereby increasing productivity. Therefore, web-hosted solutions help achieve long operational life, decrease ownership cost, and offer excellent investment returns. In 2020, the life sciences end-user segment accounted for over 54% of the global laboratory information management systems market. The life sciences industry is moving toward personalized treatment for patients using cell and gene therapy technology. Adopting advanced LIMS has helped life sciences companies offer flexibility in the routine QC and improve productivity. During the COVID-19 pandemic, several LIMSs came out with COVID-19 extracting and testing workflows, complete electronic patient recording and tracking systems, comprehensive sample data traceability, scalable consumables inventory management, compliant audit trials, configurable security and permissions, flexible reporting frameworks, and integrations. These inclusions and enchantments influence the growth of LIMSs among life science end-users. It has helped vaccine vendors streamline their processes and manage crucial stages in the vaccine research development phase. In 2020, the services segment constituted over 57% of the global LIMS market share. The global LIMS services market is expected to reach over USD 1.2 billion by 2026. These services include professional expertise, training, managed and validation services, and customer support. As these services are recurring, the revenue share expects to grow during the forecast period. The segment is likely to increase its revenue share because of the increased adoption of LIMSs in diagnostic centers and laboratories. North America and Europe are projected to contribute maximum revenue to the market due to the presence of large regenerative medicine enterprises adopting LIMSs. Similarly, several labs across Europe implemented the COVID-19 specific LIMS to handle the samples and share the results faster. As the laboratories in Europe are primarily automated, implementing LIMS and configuring the existing LIMS specific to COVID-19 has not been a challenge for large public laboratories. Product • Broad-based LIMS • Industry Specific LIMS Component • Services • Software Deployment • Cloud-based LIMS • Web-hosted LIMS • On-premise LIMS End-users • Life Sciences Industry • Chemical & Energy Industries • Food, Beverage, & Agriculture Industries • Other Industries INSIGHTS BY GEOGRAPHY North America accounted for the share of over 42% of the global LIMS market in 2020. There is a large population that is involved in agriculture practices in the region. Over 3 million hectares of land are used for organic farming alone; LIMSs specific to agriculture have helped farmers automate several processes, thereby witnessing growth. The increasing adoption in oil refineries helps end-users reduce production costs, simplify laboratory operations, and comply with quality standards and regulations. Similarly, the usage of LIMS is increasing in the food and beverage segment. With the coronavirus creating havoc across North America, especially the US witnessing high mortality, testing has been performed rapidly. A high percentage of testing was handled through COVID-19-specific LIMSs installed in several laboratories, helping technicians ease works, sharing results through mails, and tracking the samples. Moreover, the US accounted for the largest share of the North American LIMS market in 2020. The shortage of skilled laboratory technicians, an increased number of diagnostic tests conducted across the country, and increased investments related to the life science industry are the major factors responsible for driving the demand for LIMS in the market. Geography • North America o US o Canada • Europe o UK o Germany o France o Italy o Spain • APAC o China o India o Japan o South Korea o Australia • Latin America o Mexico o Brazil o Argentina • Middle East & Africa o Saudi Arabia o Turkey o South Africa INSIGHTS BY VENDORS Illumina, Thermo Fisher Scientific, Abbott, LabVantage, and LabWare account for significant shares in the global market. Several companies are developing or commercializing products, expanding their manufacturing facilities, and partnering with others in the market. For instance, in 2020, Illumina introduced software for whole-genome analysis to examine rare diseases. Similarly, Thermo Fisher Scientific has made a strategic partnership with First genetics JCS to promote NGS in Russia. Several regional vendors are investing in new software in Europe, APAC, and North America. Many regional and local companies pose a threat to global players due to their innovative and cost-effective products and technologies. However, this also indicates tremendous growth opportunities both for existing and future/emerging players. Prominent Vendors • Abbott • Illumina • Thermo Fisher Scientific • LabWare • LabVantage Other Prominent Vendors • Accelerated Technologies • AgileBio • Autoscribe Informatics • Ambidata • Blomesystem • Benchling • Bio-ITech BV • CrelioHealth • CompuGroup Medical • Dassault Systèmes • Dotmatics • i-LIMS • LabLite • LabLynx • Modul-Bio • LabPLUS • Novatek • PerklinElmer • Promium • Siemens Healthineers • Sapio Sciences • Sunquest Information Systems KEY QUESTIONS ANSWERED 1. How big is the laboratory information management system market? 2. What is the LIMS market growth? 3. Which regions are likely to contribute maximum revenue to the market during the forecast period? 4. What is the growth of the LIMS market in India? 5. Who are the key players in the laboratory information management system market? 6. What growth strategies are adopted by leading players to gain market share?Read the full report: https://www.reportlinker.com/p06063361/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Mi QLED TV is likely to be powered by MediaTek MT9611 chipset and offer 32 GB RAM and 32 GB internal storage.